retatrutide clinical trial results obesity A new from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Noteworthy Focus Points That Help

Sci Rep 7:2342

To protect your health, verify that your digital health platform is LegitScript Certified, ensuring that the entity has undergone rigorous external auditing, operates in strict alignment with state and federal healthcare laws, and works exclusively with fully licensed 503A compounding pharmacies

If you or your baby have sensitivities, look for soy-free options to keep your routine as clean as possible

Stanley et al

30 Obesity FGF21 influences body weight through effects on adipose tissue, the central nervous system, and whole-body energy expenditure

Safety information The most common side effects include nausea, vomiting, diarrhea, and abdominal pain